Cardiac natriuretic peptides: From basic discovery to clinical practice

Cardiovascular Therapeutics

Volumn 29, Issue 6, 2011, Pages 362-376

  Hayek, Salim ^a   Nemer, Mona ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anaritide; ANP; BNP; Cardiac transcription factors; CNP; Congenital heart defects; GATA4; Gene regulation; Heart failure; Natriuretic peptides; Nesiritide; NKX2.5; TBX5

Indexed keywords

ANARITIDE; ATRIAL NATRIURETIC FACTOR; NATRIURETIC FACTOR; NESIRITIDE; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TBX5;

CELL DIFFERENTIATION; CLINICAL PRACTICE; CONGENITAL HEART DISEASE; GENE MUTATION; HEART DEVELOPMENT; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEART STRESS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; GENE EXPRESSION REGULATION; HEART DISEASES; HUMANS; MOLECULAR SEQUENCE DATA; MYOCARDIUM; NATRIURETIC PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 82355172800     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00152.x     Document Type: Review

References (155)

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
2. Nemer M, Lavigne JP, Drouin J, Thibault G, Gannon M, Antakly T. Expression of atrial natriuretic factor gene in heart ventricular tissue. Peptides 1986;7:1147-1152.
3. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
4. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990;168:863-870.
5. Vollmar AM, Gerbes AL, Nemer M, Schulz R. Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs. Endocrinology 1993;132:1872-1874.
6. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: Novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation 2004;110:1231-1235.
7. Scotland RS, Cohen M, Foster P, Lovell M, Mathur A, Ahluwalia A, Hobbs AJ. C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA 2005;102:14452-14457.
8. Nemer M. Genetic insights into normal and abnormal heart development. Cardiovasc Pathol 2008;17:48-54.
9. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-253.
10. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-3189.
11. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005;293:1900-1905.
12. Seidman CE, Bloch KD, Zisfein J, et al. Molecular studies of the atrial natriuretic factor gene. Hypertension 1985;7:I31-I34.
13. Flynn TG, Davies PL, Kennedy BP, de Bold ML, de Bold AJ. Alignment of rat cardionatrin sequences with the preprocardionatrin sequence from complementary DNA. Science 1985;228:323-325.
14. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 2000;97:8525-8529.
15. Sawada Y, Suda M, Yokoyama H, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem 1997;272:20545-20554.
16. Seilhamer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM, Lewicki JA, Porter JG. Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun 1989;165:650-658.
17. Sudoh T, Minamino N, Kangawa K, Matsuo H. Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Commun 1988;155:726-732.
18. Tran KL, Lu X, Lei M, Feng Q, Wu Q. Upregulation of corin gene expression in hypertrophic cardiomyocytes and failing myocardium. Am J Physiol Heart Circ Physiol 2004;287:H1625-H1631.
19. Semenov AG, Postnikov AB, Tamm NN, et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem 2009;55:489-498.
20. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-1078.
21. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC, Jr. Immunoreactivity and guanosine 3', 5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007;49:1114-1119.
22. Mair J. Clinical significance of pro-B-type natriuretic peptide glycosylation and processing. Clin Chem 2009;55:394-397.
23. Galipeau J, Nemer M, Drouin J. Ventricular activation of the atrial natriuretic factor gene in acute myocardial infarction. N Engl J Med 1988;319:654-655.
24. Dagnino L, Lavigne JP, Nemer M. Increased transcripts for B-type natriuretic peptide in spontaneously hypertensive rats. Quantitative polymerase chain reaction for atrial and brain natriuretic peptide transcripts. Hypertension 1992;20:690-700.
25. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, Imura H. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system". J Clin Invest 1992;90:1145-1149.
26. Horio T, Tokudome T, Maki T, et al. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 2003;144:2279-2284.
27. Del Ry S, Cabiati M, Lionetti V, Emdin M, Recchia FA, Giannessi D. Expression of C-type natriuretic peptide and of its receptor NPR-B in normal and failing heart. Peptides 2008;29:2208-2215.
28. Kalra PR, Clague JR, Bolger AP, Anker SD, Poole-Wilson PA, Struthers AD, Coats AJ. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003;107:571-573.
29. Wu C, Wu F, Pan J, Morser J, Wu Q. Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem 2003;278:25847-25852.
30. Stingo AJ, Clavell AL, Heublein DM, Wei CM, Pittelkow MR, Burnett JC, Jr. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 1992;263:H1318-H1321.
31. Nemer M, Chamberland M, Sirois D, et al. Gene structure of human cardiac hormone precursor, pronatriodilatin. Nature 1984;312:654-656.
32. Argentin S, Nemer M, Drouin J, Scott GK, Kennedy BP, Davies PL. The gene for rat atrial natriuretic factor. J Biol Chem 1985;260:4568-4571.
33. Yang-Feng TL, Floyd-Smith G, Nemer M, Drouin J, Francke U. The pronatriodilatin gene is located on the distal short arm of human chromosome 1 and on mouse chromosome 4. Am J Hum Genet 1985;37:1117-1128.
34. Ogawa Y, Itoh H, Yoshitake Y, Inoue M, Yoshimasa T, Serikawa T, Nakao K. Molecular cloning and chromosomal assignment of the mouse C-type natriuretic peptide (CNP) gene (Nppc): Comparison with the human CNP gene (NPPC). Genomics 1994;24:383-387.
35. John SW, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995;267:679-681.
36. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000;97:4239-4244.
37. Chusho H, Tamura N, Ogawa Y, et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci U S A 2001;98:4016-4021.
38. Singh S, Lowe DG, Thorpe DS, et al. Membrane guanylate cyclase is a cell-surface receptor with homology to protein kinases. Nature 1988;334:708-712.
39. Gerzer R, Witzgall H, Tremblay J, Gutkowska J, Hamet P. Rapid increase in plasma and urinary cyclic GMP after bolus injection of atrial natriuretic factor in man. J Clin Endocrinol Metab 1985;61:1217-1219.
40. Tremblay J, Gerzer R, Vinay P, Pang SC, Beliveau R, Hamet P. The increase of cGMP by atrial natriuretic factor correlates with the distribution of particulate guanylate cyclase. FEBS Lett 1985;181:17-22.
41. Drewett JG, Garbers DL. The family of guanylyl cyclase receptors and their ligands. Endocr Rev 1994;15:135-162.
42. Lopez MJ, Wong SK, Kishimoto I, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995;378:65-68.
43. Oliver PM, Fox JE, Kim R, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A 1997;94:14730-14735.
44. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K. Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res 2000;86:841-845.
45. Chang MS, Lowe DG, Lewis M, Hellmiss R, Chen E, Goeddel DV. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature 1989;341:68-72.
46. Koller KJ, Lowe DG, Bennett GL, Minamino N, Kangawa K, Matsuo H, Goeddel DV. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 1991;252:120-123.
47. Schulz S, Chinkers M, Garbers DL. The guanylate cyclase/receptor family of proteins. FASEB J 1989;3:2026-2035.
48. Nagase M, Katafuchi T, Hirose S, Fujita T. Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats. J Hypertens 1997;15:1235-1243.
49. Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL. Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci U S A 2004;101:17300-17305.
50. Bartels CF, Bukulmez H, Padayatti P, et al. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 2004;75:27-34.
51. Fuller F, Porter JG, Arfsten AE, et al. Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J Biol Chem 1988;263:9395-9401.
52. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, Smithies O. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A 1999;96:7403-7408.
53. Cohen D, Koh GY, Nikonova LN, Porter JG, Maack T. Molecular determinants of the clearance function of type C receptors of natriuretic peptides. J Biol Chem 1996;271:9863-9869.
54. Anand-Srivastava MB, Sairam MR, Cantin M. Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. J Biol Chem 1990;265:8566-8572.
55. Berl T, Mansour J, Teitelbaum I. ANP stimulates phospholipase C in cultured RIMCT cells: roles of protein kinases and G protein. Am J Physiol 1991;260:F590-F595.
56. Resink TJ, Scott-Burden T, Baur U, Jones CR, Buhler FR. Atrial natriuretic peptide induces breakdown of phosphatidylinositol phosphates in cultured vascular smooth-muscle cells. Eur J Biochem 1988;172:499-505.
57. Sabbatini ME. Natriuretic peptides as regulatory mediators of secretory activity in the digestive system. Regul Pept 2009;154:5-15.
58. Sabbatini ME, Rodriguez M, di Carlo MB, Davio CA, Vatta MS, Bianciotti LG. C-type natriuretic peptide enhances amylase release through NPR-C receptors in the exocrine pancreas. Am J Physiol Gastrointest Liver Physiol 2007;293:G987-994.
59. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145-151.
60. Brown LA, Nunez DJ, Wilkins MR. Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat. J Clin Invest 1993;92:2702-2712.
61. Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000;167:239-246.
62. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC, Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988;62:191-195.
63. Sabrane K, Kruse MN, Fabritz L, et al. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 2005;115:1666-1674.
64. Holtwick R, Gotthardt M, Skryabin B, et al. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A 2002;99:7142-7147.
65. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: Insights from genetically modified mice. Circ Res 2003;93:907-916.
66. Kishimoto I, Dubois SK, Garbers DL. The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: Acute handling of sodium and water in response to volume expansion. Proc Natl Acad Sci U S A 1996;93:6215-6219.
67. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986;324:473-476.
68. Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 1987;326:697-698.
69. Light DB, Corbin JD, Stanton BA. Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase. Nature 1990;344:336-339.
70. Gambaryan S, Wagner C, Smolenski A, et al. Endogenous or overexpressed cGMP-dependent protein kinases inhibit cAMP-dependent renin release from rat isolated perfused kidney, microdissected glomeruli, and isolated juxtaglomerular cells. Proc Natl Acad Sci U S A 1998;95:9003-9008.
71. Kudo T, Baird A. Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factor. Nature 1984;312:756-757.
72. Cherradi N, Brandenburger Y, Rossier MF, Vallotton MB, Stocco DM, Capponi AM. Atrial natriuretic peptide inhibits calcium-induced steroidogenic acute regulatory protein gene transcription in adrenal glomerulosa cells. Mol Endocrinol 1998;12:962-972.
73. Itoh H, Nakao K, Katsuura G, et al. Centrally infused atrial natriuretic polypeptide attenuates exaggerated salt appetite in spontaneously hypertensive rats. Circ Res 1986;59:342-347.
74. Samson WK, Aguila MC, Martinovic J, Antunes-Rodrigues J, Norris M. Hypothalamic action of atrial natriuretic factor to inhibit vasopressin secretion. Peptides 1987;8:449-454.
75. Schultz HD, Steele MK, Gardner DG. Central administration of atrial peptide decreases sympathetic outflow in rats. Am J Physiol 1990;258:R1250-1256.
76. Knowles JW, Esposito G, Mao L, et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 2001;107:975-984.
77. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A 2001;98:2703-2706.
78. Holtwick R, van Eickels M, Skryabin BV, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003;111:1399-1407.
79. Tsuneyoshi H, Nishina T, Nomoto T, et al. Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair. Circulation 2004;110:II174-179.
80. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995;25:227-234.
81. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127-1134.
82. Kapoun AM, Liang F, O'Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: Fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004;94:453-461.
83. He JG, Chen YL, Chen BL, Huang YY, Yao FJ, Chen SL, Dong YG. B-type natriuretic peptide attenuates cardiac hypertrophy via TGF-beta1/smad7 pathway in vivo and in vitro. Clin Exp Pharmacol Physiol 2009 Aug 28.
84. Li P, Wang D, Lucas J, et al. Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res 2008;102:185-192.
85. Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun 1991;177:927-931.
86. Shinomiya M, Tashiro J, Saito Y, et al. C-type natriuretic peptide inhibits intimal thickening of rabbit carotid artery after balloon catheter injury. Biochem Biophys Res Commun 1994;205:1051-1056.
87. Itoh T, Nagaya N, Murakami S, et al. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;170:1204-1211.
88. Murakami S, Nagaya N, Itoh T, et al. C-type natriuretic peptide attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004;287:L1172-L1177.
89. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: A new lipolytic pathway in human adipocytes. FASEB J 2000;14:1345-1351.
90. Sengenes C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M, Galitzky J. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 2003;278:48617-48626.
91. Cao LH, Yang XL. Natriuretic peptides and their receptors in the central nervous system. Prog Neurobiol 2008;84:234-248.
92. Zeller R, Bloch KD, Williams BS, Arceci RJ, Seidman CE. Localized expression of the atrial natriuretic factor gene during cardiac embryogenesis. Genes Dev 1987;1:693-698.
93. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 2007;12:331-343.
94. Grepin C, Nemer G, Nemer M. Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. Development 1997;124:2387-2395.
95. Kuo CT, Morrisey EE, Anandappa R, et al. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev 1997;11:1048-1060.
96. Molkentin JD, Lin Q, Duncan SA, Olson EN. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev 1997;11:1061-1072.
97. Crispino JD, Lodish MB, Thurberg BL, Litovsky SH, Collins T, Molkentin JD, Orkin SH. Proper coronary vascular development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors. Genes Dev 2001;15:839-844.
98. Clark KL, Yutzey KE, Benson DW. Transcription factors and congenital heart defects. Annu Rev Physiol 2006;68:97-121.
99. Charron F, Nemer M. GATA transcription factors and cardiac development. Semin Cell Dev Biol 1999;10:85-91.
100. Charron F, Paradis P, Bronchain O, Nemer G, Nemer M. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol Cell Biol 1999;19:4355-4365.
101. McBride K, Nemer M. Regulation of the ANF and BNP promoters by GATA factors: Lessons learned for cardiac transcription. Can J Physiol Pharmacol 2001;79:673-681.
102. Grepin C, Dagnino L, Robitaille L, Haberstroh L, Antakly T, Nemer M. A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol Cell Biol 1994;14:3115-3129.
103. Wang J, Paradis P, Aries A, Komati H, Lefebvre C, Wang H, Nemer M. Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4. Mol Cell Biol 2005;25:9829-9844.
104. Morin S, Paradis P, Aries A, Nemer M. Serum response factor-GATA ternary complex required for nuclear signaling by a G-protein-coupled receptor. Mol Cell Biol 2001;21:1036-1044.
105. He Q, Mendez M, LaPointe MC. Regulation of the human brain natriuretic peptide gene by GATA-4. Am J Physiol Endocrinol Metab 2002;283:E50-E57.
106. Thuerauf DJ, Hanford DS, Glembotski CC. Regulation of rat brain natriuretic peptide transcription. A potential role for GATA-related transcription factors in myocardial cell gene expression. J Biol Chem 1994;269:17772-17775.
107. Charron F, Tsimiklis G, Arcand M, et al. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev 2001;15:2702-2719.
108. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A 2004;101:6975-6980.
109. Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley AW, Jr., Izumo S, Markham BE. Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc Natl Acad Sci U S A 1997;94:7543-7548.
110. Lyons I, Parsons LM, Hartley L, Li R, Andrews JE, Robb L, Harvey RP. Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene Nkx2-5. Genes Dev 1995;9:1654-1666.
111. Schott JJ, Benson DW, Basson CT, et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 1998;281:108-111.
112. Durocher D, Chen CY, Ardati A, Schwartz RJ, Nemer M. The atrial natriuretic factor promoter is a downstream target for Nkx-2. 5 in the myocardium. Mol Cell Biol 1996;16:4648-4655.
113. Small EM, Krieg PA. Transgenic analysis of the atrialnatriuretic factor (ANF) promoter: Nkx2-5 and GATA-4 binding sites are required for atrial specific expression of ANF. Dev Biol 2003;261:116-131.
114. Durocher D, Charron F, Warren R, Schwartz RJ, Nemer M. The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors. EMBO J 1997;16:5687-5696.
115. Kuo H, Chen J, Ruiz-Lozano P, Zou Y, Nemer M, Chien KR. Control of segmental expression of the cardiac-restricted ankyrin repeat protein gene by distinct regulatory pathways in murine cardiogenesis. Development 1999;126:4223-4234.
116. Nemer G, Nemer M. Regulation of heart development and function through combinatorial interactions of transcription factors. Ann Med 2001;33:604-610.
117. Bruneau BG, Nemer G, Schmitt JP, et al. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 2001;106:709-721.
118. Basson CT, Bachinsky DR, Lin RC, et al. Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat Genet 1997;15:30-35.
119. Bamshad M, Lin RC, Law DJ, et al. Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nat Genet 1997;16:311-315.
120. Habets PE, Moorman AF, Clout DE, et al. Cooperative action of Tbx2 and Nkx2.5 inhibits ANF expression in the atrioventricular canal: Implications for cardiac chamber formation. Genes Dev 2002;16:1234-1246.
121. Christoffels VM, Hoogaars WM, Tessari A, Clout DE, Moorman AF, Campione M. T-box transcription factor Tbx2 represses differentiation and formation of the cardiac chambers. Dev Dyn 2004;229:763-770.
122. Lickert H, Takeuchi JK, Von Both I, et al. Baf60c is essential for function of BAF chromatin remodelling complexes in heart development. Nature 2004;432:107-112.
123. Debrus S, Rahbani L, Marttila M, Delorme B, Paradis P, Nemer M. The zinc finger-only protein Zfp260 is a novel cardiac regulator and a nuclear effector of alpha1-adrenergic signaling. Mol Cell Biol 2005;25:8669-8682.
124. Morin S, Charron F, Robitaille L, Nemer M. GATA-dependent recruitment of MEF2 proteins to target promoters. EMBO J 2000;19:2046-2055.
125. Ganga M, Espinoza HM, Cox CJ, Morton L, Hjalt TA, Lee Y, Amendt BA. PITX2 isoform-specific regulation of atrial natriuretic factor expression: Synergism and repression with Nkx2.5. J Biol Chem 2003;278:22437-22445.
126. Lu JR, McKinsey TA, Xu H, Wang DZ, Richardson JA, Olson EN. FOG-2, a heart- and brain-enriched cofactor for GATA transcription factors. Mol Cell Biol 1999;19:4495-4502.
127. Kim TG, Chen J, Sadoshima J, Lee Y. Jumonji represses atrial natriuretic factor gene expression by inhibiting transcriptional activities of cardiac transcription factors. Mol Cell Biol 2004;24:10151-10160.
128. Fischer A, Klattig J, Kneitz B, et al. Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. Mol Cell Biol 2005;25:8960-8970.
129. Bruneau BG, Bao ZZ, Fatkin D, et al. Cardiomyopathy in Irx4-deficient mice is preceded by abnormal ventricular gene expression. Mol Cell Biol 2001;21:1730-1736.
130. Bhalla SS, Robitaille L, Nemer M. Cooperative activation by GATA-4 and YY1 of the cardiac B-type natriuretic peptide promoter. J Biol Chem 2001;276:11439-11445.
131. Lavallee G, Andelfinger G, Nadeau M, Lefebvre C, Nemer G, Horb ME, Nemer M. The Kruppel-like transcription factor KLF13 is a novel regulator of heart development. EMBO J 2006;25:5201-5213.
132. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-1374.
133. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009;341-66.
134. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-322.
135. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
136. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44:1328-1333.
137. Fonarow GC, Peacock WF, Horwich TB, Phillips CO, Givertz MM, Lopatin M, Wynne J. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol 2008;101:231-237.
138. Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol 2009;54:1099-1106.
139. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992;327:685-691.
140. Betti I, Castelli G, Barchielli A, et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail 2009;15:377-384.
141. McDonagh TA, McDonald K, Maisel AS. Screening for asymptomatic left ventricular dysfunction using B-type natriuretic Peptide. Congest Heart Fail 2008;14:5-8.
142. Weder AB, Sekkarie MA, Takiyyuddin M, Schork NJ, Julius S. Antihypertensive and hypotensive effects of atrial natriuretic factor in men. Hypertension 1987;10:582-589.
143. Fifer MA, Molina CR, Quiroz AC, et al. Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. Am J Cardiol 1990;65:211-216.
144. Kitashiro S, Sugiura T, Takayama Y, Tsuka Y, Izuoka T, Tokunaga S, Iwasaka T. Long-term administration of atrial natriuretic peptide in patients with acute heart failure. J Cardiovasc Pharmacol 1999;33:948-952.
145. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998;31:674-680.
146. Sward K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: A randomized placebo-controlled trial. Crit Care Med 2004;32:1310-1315.
147. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002;287:1531-1540.
148. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-1491.
149. Behera SK, Zuccaro JC, Wetzel GT, Alejos JC. Nesiritide improves hemodynamics in children with dilated cardiomyopathy: A pilot study. Pediatr Cardiol 2009;30:26-34.
150. George I, Morrow B, Xu K, et al. Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury. Am J Physiol Heart Circ Physiol 2009;297:H708-H717.
151. Chen HH, Martin FL, Gibbons RJ, et al. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: A proof of concept study. Heart 2009;95:1315-1319.
152. Hillock RJ, Frampton CM, Yandle TG, Troughton RW, Lainchbury JG, Richards AM. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 2008;94:617-622.
153. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001;37:1820-1826.
154. Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC, Jr. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009;49:668-673.
155. Mueller C. Cost-effectiveness of B-type natriuretic peptide testing. Congest Heart Fail 2008;14:35-37.